Amylin, India's Biocon Join Hands For Peptide-Based Diabetes Compound
• By PharmAsia News
MUMBAI - Biocon, India's largest biotech with products ranging from insulins to monoclonal antibodies and Amylin - developers of insulin injection Byetta (exanetide) - have agreed to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
